When diagnosed with prostate cancer, genetic precision can guide decisions between patients and their doctors. Click below to learn more and download this infographic.

Learn how a hereditary cancer risk assessment is an important option for prostate cancer patients during Prostate Cancer Awareness Month.

Prolaris & MyRisk


Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.